Safety-net hospitals push for 2-year delay in DSH cuts

America’s Essential Hospitals has announced a new advocacy and advertising campaign seeking a delay in cuts to Medicaid Disproportionate Share Hospital (DSH) payments, which are set to be reduced by $2 billion in the current fiscal year.

The payments had been set to be reduced as part of the Affordable Care Act (ACA), with policy makers reasoning at the time that increased insurance coverage meant uncompensated care would decrease. The cuts were then delayed several times, but finally went into effect for fiscal year 2018. The $2 billion cut would increase by $1 billion each year through 2023, maxing out at $8 billion each in 2024 and 2025.

“The $2 billion cut in the current fiscal year undermines vital support for hospitals that care for many uninsured and underinsured patients,” America’s Essential Hospitals said in a press release.

Hospital groups have advocated for another delay to the cuts, to no avail. The America’s Essential Hospitals’ push hopes to insert such a provision in the government funding legislation which will need to be passed later this month to avert a shutdown.

The group’s president and CEO Bruce Seigel, MD, MPH, has previously said the repeal of the ACA’s individual mandate will only exacerbate the problems for their member facilities, potentially leading to services being scaled back or hospitals being closed altogether.

Similar warnings have come from financial analysts predicting a “wave” of bankruptcies among hospitals. The long-delayed DSH cuts would be a major factor, with Winston & Strawn partner David Neier telling Bloomberg it would “single-handedly throw hospitals into immediate financial distress.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met. 

When regulating AI-equipped medical devices, the FDA might take a page from the Department of Transportation’s playbook for overseeing AI-equipped vehicles. These run the gamut from assisting human drivers to fully taking the wheel. 

Kit Crancer, RBMA board member, speaks with Radiology Business about key legislative developments on the Hill that will affect the specialty.